-
Press Release
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
-
Press Release
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
-
Story
What's next in Neuroscience drug discovery -
Press Release
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
-
Press Release
Novartis erzielte im Jahr 2025 eine Umsatzsteigerung im hohen einstelligen Prozentbereich, eine Kerngewinnmarge von 40% sowie weitere Fortschritte in der Pipeline
-
Press Release
Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025
-
Press Release
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
-
Press Release
Novartis and US government reach agreement on lowering drug prices in the US
-
Press Release
Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses
-
Press Release
Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets
-
Press Release
Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance
-
Press Release
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline